Keyphrases
Clinical Benefit
100%
Systemic Therapy
100%
Magnitude of Clinical Benefit Scale
100%
European Society
85%
Medical Oncology
85%
Systemic Treatment
28%
Platinum-based Chemotherapy
28%
Bevacizumab
28%
Randomized Trial
28%
Chemotherapy
14%
Treatment Options
14%
Clinical Decision-making
14%
Phase II Study
14%
PARP Inhibitor (PARPi)
14%
Maintenance Treatment
14%
Chemotherapy Treatment
14%
PubMed Search
14%
Significant Benefit
14%
Paclitaxel
14%
Nineteen
14%
Non-platinum
14%
Epithelial Ovarian Cancer
14%
Life Data
14%
Assessment of Quality of Life
14%
Wee1 Inhibitors
14%
Overall Survival Benefit
14%
Substantial Clinical Benefit
14%
Sensitive Settings
14%
Platinum Sensitivity
14%
Adavosertib
14%
Benefit Measure
14%
Recurrent Ovarian Cancer
14%
Platinum-resistant Disease
14%
Platinum-resistant Ovarian Cancer
14%
Platinum Resistance
14%
Medicine and Dentistry
Systemic Therapy
100%
Medical Oncology
100%
Chemotherapy
50%
Bevacizumab
33%
Recurrent Ovarian Cancer
33%
Disease
16%
Overall Survival
16%
Clinical Decision Making
16%
Quality of Life
16%
Arm
16%
Maintenance Therapy
16%
PARP Inhibitor
16%
Paclitaxel
16%
Krukenberg Tumor
16%
Adavosertib
16%